Dualitas Therapeutics, Inc.

Dualitas Therapeutics, Inc. is a biotechnology company pioneering next-generation bispecific antibody therapies for immunology and inflammation (I&I). Dualitas' portfolio, built from its DualScreen™ discovery engine, includes development candidate DTX-102 in rheumatoid arthritis, DTX-103 in allergic disease and DTX-101 in dermatologic and gastrointestinal autoimmune disease, alongside additional discoveries based on cell-surface proximity biology and novel co-target pairing. While advancing its own pipeline, Dualitas offers a variety of strategic collaboration opportunities to extend the impact of its discovery capabilities, ranging from existing pipeline programs to identifying de novo BsAbs to establishing programs in disease areas beyond I&I.